Luxshare Shares Rise as First-Half Profit Jumps 18% 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
PayPal Shares Sink as $50 Billion Takeover Bid Collapses 
Nvidia Revenue Soars 106% as AI Demand Hits ‘Inflection Point’ 
Jefferies Names AMEC Top China Semiconductor Equipment Pick 
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
Google Changes EU Spam Policy Amid Antitrust Scrutiny 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
Street Poller Media and The Boom of the Street Interview Ad Industry 
Toyota Global Sales Fall as China Demand Slumps 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
Meta, U.S. States Discuss Settlement in Teen Addiction Trial 
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
OpenAI AI Agent Swarm Behind Hugging Face Hack 
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
Add as a preferred source on Google
SAN DIEGO, April 17, 2018 -- Retrophin, Inc. (NASDAQ:RTRX) today announced it will report first quarter 2018 financial results on Tuesday, May 1, 2018 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.
| Conference Call Information | ||
| Date: | Tuesday, May 1, 2018 | |
| Time: | 4:30 p.m. ET | |
| Dial-in numbers: | +1 (855) 219-9219 (U.S.) or +1 (315) 625-6891 (International) | |
| Confirmation code: | 1169697 | |
| Live webcast: | Retrophin.com in the “Events & Presentations” section of the “Investors” page | |
A replay of the call will be available from 7:30 p.m. ET, May 1, 2018 to 7:30 p.m. ET, May 8, 2018. The replay number is +1 (855) 859-2056 (U.S.) or +1 (404) 537-3406 (International), confirmation code 1169697.
About Retrophin
Retrophin is a biopharmaceutical company specializing in identifying, developing and delivering life-changing therapies to people living with rare diseases. The Company’s approach centers on its pipeline featuring late-stage assets targeting rare diseases with significant unmet medical needs, including fosmetpantotenate for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood, and sparsentan for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), disorders characterized by progressive scarring of the kidney often leading to end-stage renal disease. Research in additional rare diseases is also underway, including a joint development arrangement evaluating the potential of CNSA-001 in phenylketonuria (PKU), a rare genetic metabolic condition that can lead to neurological and behavioral impairment. Retrophin’s R&D efforts are supported by revenues from the Company’s commercial products Chenodal®, Cholbam® and Thiola®.
Contact:
Chris Cline, CFA
Vice President, Investor Relations & Corporate Communications
646-564-3680
[email protected]
